Jonathan Jackson

Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School and executive director of the CARE Research Center, joins to discuss the new Alzheimer's drug lecanemab. He highlights the groundbreaking diversity in clinical trials but raises concerns about the lack of data for underrepresented groups, particularly Black Americans. The conversation delves into the significance of inclusive trial designs and the urgent need to reevaluate standards in drug testing to ensure all populations at risk can benefit from advancements in treatment.